Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Novo’s Insulin Degludec Faces Advisory Cmte. Scrutiny On Hypoglycemic Benefit, CV Safety

Nov 06 2012

• By Sue Sutter

Related Content

Novo Highlights Degludec's Advantage Versus Lantus In Fewer Night-Time Hypoglycemic Events

Dec 30 2010

Degludec Advisory Committee Is Another De Facto Delay For Novo

Jul 18 2012

New Long-Acting Insulin Offerings Could Derail Lantus Franchise

Jun 18 2012

Related Companies

Novo Nordisk A/S

Sanofi

Additional Topics

United States Advisory Committees BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window